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Abstract: Strategies for site-specific modification of proteins have increased in number, complexity,
and specificity over the last years. Such modifications hold the promise to broaden the use of existing
biopharmaceuticals or to tailor novel proteins for therapeutic or diagnostic applications. The recent
quest for next-generation antibody–drug conjugates (ADCs) sparked research into techniques with
site selectivity. While purely chemical approaches often impede control of dosage or locus of
derivatization, naturally occurring enzymes and proteins bear the ability of co- or post-translational
protein modifications at particular residues, thus enabling unique coupling reactions or protein
fusions. This review provides a general overview and focuses on chemo-enzymatic methods including
enzymes such as formylglycine-generating enzyme, sortase, and transglutaminase. Applications for
the conjugation of antibodies and antibody mimetics are reported.
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1. Introduction
1.1. Antibody–Drug Conjugates
In the fight against cancer, antibody–drug conjugates (ADC) have gained considerable attention,
especially since the market release of Kadcyla and Adcetris, which have doubled in yearly sales since
2013, closing in on a billion dollars [1,2]. A vast number of new ADCs are in the pipeline, with seven
of them in pivotal clinical trials [3]. A factor fueling the success of ADCs is the promising expansion
of the therapeutic window compared to “naked” therapeutic monoclonal antibodies (mABs) and
classical chemotherapy. Furthermore, this approach could revive antibodies with suitable affinities
yet insufficient cytotoxicity, and highly potent drugs unfavorable for unspecific systemic application.
Improvement of therapeutic efficacy has been proven for the trastuzumab–maytansine conjugate
T-DM1 on tumor models refractory to trastuzumab [4]. However, said potential therapeutic window is
limited by the heterogeneity, stability, and pharmacokinetics of current ADCs and could be restored
by site-specific conjugation strategies [5,6]. The drug to antibody ratio (DAR) emerged as a key term
in the discussion of the ideal ADC, which has to be high enough to provide sufficient therapeutic
potency as well as low enough to not generate heavily drug-modified conjugates with impaired
binding properties, stability, and circulation half-life [7,8]. Depending on the properties of the drug,
the ideal DAR for most ADCs is between 2 and 4 [7,9]. Coupling strategies for first generation ADCs
have been exclusively chemical with random coupling of thiol groups on reduced cysteines, of side
chain amine groups on lysines and aldehyde groups on oxidized glycostructures [10]. The abundance
of such modification targets leads to a broad distribution of DARs. Subsequent strategies therefore
focused on altering interchain disulfide bonds, changing respective cysteines to serines or introducing
new free cysteines [11], as utilized for the THIOMAB conjugation strategy [12,13], or modulating the
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reactivity of specific cysteine residues for the pi-clamp strategy [14]. In contrast, this review will focus
on enzyme-based strategies to create homogenous antibody–drug conjugates (Figure 1).
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1.2. Antibody Fragments and Mimetics 
Antibody fragments and mimetics were created to generate economical and more convenient high-
affinity proteins with alternative properties, though in part similar to those of full antibodies. Intended 
differences to full antibodies are their smaller size and the possibility to be produced in prokaryotic 
cells. Some of these mimetics are directly derived from their full antibody counterparts, like antigen-
binding fragments (Fab), single-chain variable fragments (scFv) or domain antibodies, such as VHH 
domains (also termed Nanobodies). Nanobodies are derived from camelid heavy–chain–only 
antibodies and have been used extensively for imaging and even therapeutic applications [15]. They 
inhibited antigen binding or were loaded with toxins and thereby delayed tumor growth [16,17]. ScFv 
antibodies for therapy are human or humanized light and heavy chain variable fragments fused by a 
flexible (glycine-serine) linker. They have shown increased distribution across tumors while retaining 
antigen affinity. Their potential use for cancer therapy has been discussed [18–20] with Blincyto 
(blinatumomab, anti CD3 scFv–anti CD19 scFv) being an approved drug. Other antibody mimetics 
consist of conserved protein scaffolds with variable affinity regions mimicking the complementary 
determining regions of antibodies. Designed ankyrin repeat proteins (DARPins) showed high 
specificity and good tumor penetration due to their small size and stability [21]. They consist of linker 
connected turn–helix–helix motifs, typically three plus two capping domains, which form the antigen 
binding surface. Repebodies, similar to DARPins, are composed of repetitive motifs called leucin-rich 
repeats organized in a β–strand–turn–α–helix structure [22]. Derived from the α-helical Z domain of 
staphylococcus protein A, Affibodies, the smallest of the antibody mimetics with around 6 kDa, are 
mostly used for imaging [23]. A lot of the pros and cons of antibody fragments mimetics are common, 
such as their ability to penetrate tumors, but also their relatively short half-life in blood circulation and, 
due to the lack of an Fc part, their missing antibody-dependent cell-mediated cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC [24,25]. While the shorter circulation time of antibody 
mimetics narrows the therapeutic window for cancer therapy, it is otherwise beneficial for diagnostic 
approaches, as the patient’s exposure to substances such as radiolabels is shorter. The enhanced tumor 
penetration, due to smaller size and typically lower affinities, can be advantageous in the treatment of 
solid tumors. Whereas whole antibodies usually accumulate between tumor interstitium and tumor 
surface cells, antibody fragments and mimetics are able to reach the inner tissue faster [24,26]. Antibody 
mimetics can benefit from modification, like PEGylation and fusion to an albumin-binding domain for 
longer circulation and site-specific drug coupling for enhanced toxicity. 
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1.2. Antibody Fragments and Mimetics
Antibody fragments and mimetics were created to generate economical and more convenient
high-affinity proteins with alternative properties, though in part similar to those of full antibodies.
Intended differences to full antibodies are their smaller size and the possibility to be produced in
prokaryotic cells. Some of these mimetics are directly derived from their full antibody counterparts, like
antigen-binding fragments (Fab), single-chain variable fragments (scFv) or domain antibodies, such as
VHH domains (also termed Nanobodies). Nanobodies are derived from camelid heavy–chain–only
antibodies and have been used extensively for imaging and even therapeutic applications [15]. They
inhibited antigen binding or were loaded with toxins and thereby delayed tumor growth [16,17]. ScFv
antibodies for therapy are human or humanized light and heavy chain variable fragments fused by
a flexible (glycine-serine) linker. They have shown increased distribution across tumors while retaining
antigen affinity. Their potential use for cancer therapy has been discussed [18–20] with Blincyto
(blinatumomab, anti CD3 scFv–anti CD19 scFv) being an approved drug. Other antibody mimetics
consist of conserved protei scaffolds with variable affinity regions mimicking the complementary
determining regi ns of antibodies. Designed ankyrin repeat proteins (DARPins) showed high
specifi ity and good tumor penetra ion due to th ir small size and stability [21]. They consist of linker
co nected turn–helix–helix motifs, typically three plus two capping domains, wh ch form the a tigen
binding surface. Repebodies, similar to DARPins, are composed of repetitive motifs called leucin-rich
repeats rganized in a β–strand–turn–α–helix structure [22]. Derived from the α-helical Z dom in of
staph lococcus protei A, Affibodies, the smallest f the antibo mimetics with around 6 kDa, are
mostly us d for imaging [23]. A lot of the pros and cons of antibody fr gments mimetics are common,
such as their ability to penetrate tu ors, but als their relatively short half-life in bl od circulation ,
due to the lack of an Fc part, their missing antibody-dependent cell-mediated cytotoxicity (ADCC)
and complement-dependent cytotoxicity (CDC [24,25]. While the shorter circulation time of antibody
mimetics narrows the therapeutic window for cancer therapy, it is otherwise beneficial for diagnostic
approaches, as the patient’s exposure to substances such as radiolabels is shorter. The enhanced tumor
penetration, due to smaller size and typically lower affinities, can be advantageous in the treatment
of solid tumors. Whereas whole antibodies usually accumulate between tumor interstitium and
tumor surface cells, antibody fragments and mimetics are able to reach the inner tissue faster [24,26].
Antibody mimetics can benefit from modification, like PEGylation and fusion to an albumin-binding
domain for longer circulation and site-specific drug coupling for enhanced toxicity.
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2. Site-Specific Protein Modification Strategies
2.1. Formylglycine-Generating Enzymes
First found during an investigation of the multiple sulfatase deficiency, formylglycine-generating
enzymes (FGE) have the ability to convert cysteines site-specifically to formylglycines, presenting
an aldehyde residue unique in proteins and suitable for bio-orthogonal coupling (Figure 2) [27,28].
Their natural substrates are sulfatases bearing a highly conserved hexapeptide, in which the cysteine is
converted to formylglycine in the endoplasmic reticulum (ER) [29,30]. FGEs can be found in a variety
of organisms, both prokaryotic and eukaryotic, suggesting possible various in vivo as well as in vitro
applications. Since its discovery in 2003, human FGE (hFGE) has been predominantly employed
in formylglycine conversion in the eukaryotic context [31,32]. When overexpressed, excess hFGE is
truncated and secreted from the ER. This secreted form is still catalytically functional and utilizable
for in vitro reactions [33]. For prokaryotic systems, different FGEs are available, with Mycobacterium
tuberculosis, Streptomyces coelicolor, and Thermomonospora curvata leading the way. Formylglycine,
as a novel posttranslational modification, has drawn interest in the field of site-specific modification.
Carrico et al. coined the term “aldehyde tag” in 2007 for the short universal FGE recognition motif
LCTPSR, later shortened to CXPXR [34,35]. They used this tag for N- or C-terminal protein modification
in E. coli co-expressed with M. tuberculosis FGE [36]. The tag was also introduced in a CHO (Chinese
Hamster Ovary) cell system for IgG-Fc and whole antibody modification, showing the preservation of
binding functionalities, as well as for labelling of cytosolic and cell surface proteins [37]. For the
generation of site-specific coupled antibodies and antibody fragments expression platforms for
aldehyde tagged proteins were tested in both E. coli and CHO cells while stably coexpressing hFGE [38].
The effect of positioning of the drug in ADCs has been addressed and aldehyde tag functionality at
different sites of an IgG1 antibody has been validated. While aggregation occurred after introduction
at certain positions, especially in the CH2 and CH3 domains, for the most part the implemented tags
were applicable. The flexibility of the tags use was thus extended to almost all generally accessible
areas of the antibody [39]. Formylglycine conversion rates of 75% to over 90% could be achieved,
yet total conversion still remains an issue. In an attempt to enhance conversion, different media and
copper(II) supplementation were tested yielding higher conversion rates even with 5 µM copper
addition. Media composition seems to play a crucial role in conversion results as well, but details
remain elusive [40]. Copper supplementation and reconstitution of FGE in vitro have been discussed
in the light of new findings regarding the mechanism of the FGE catalysis. Human FGE converts the
substrate cysteine after disulfide formation with the Cys-341 in an oxygenase-type reaction requiring
molecular oxygen and a reductant [41,42]. Recently copper(I) was proposed as a cofactor [43]. In vitro
reconstitution with copper could successfully increase the catalytic efficiency of bacterial FGEs [44,45].
The overall similarity of the mycobacterium tuberculosis and S. coelicolor FGE to hFGE including the
two cysteines in the catalytic center suggests a common mechanism [46]. Setbacks of the method
including precipitation in vitro have been reported, especially in high ionic strength reaction buffers,
and diol formation of the formylglycine [44]. At the same time, the possibility of using this enzyme
strategy in eukaryotic and prokaryotic environments, as well as both in vitro and in cells, and the
number of aldehyde group-based coupling chemistries, e.g., hydrazino–iso–Pictet–Spengler, the Wittig
reaction or trapped-Knoevenagel, show its flexibility.
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structures of the peptidoglycane cell wall [47]. Staphylococcus aureus sortase A (srtA) is the most 
frequently used enzyme for site-specific protein labelling with this transpeptidase reaction (Figure 3). 
Its natural substrate recognition motif is the pentapeptide LPXTG, where X is usually glutamic acid, 
besides aspartic acid or lysine [48]. In a ping-pong hydrolytic shunt-like mechanism, srtA binds the 
LPXTG substrate, hydrolyzes the backbone between threonine and glycine, and generates an acyl-
enzyme intermediate. The terminal amine of the oligoglycine then acts as a nucleophile, resulting in an 
amide bond formation with the C-terminal threonine of the substrate [49,50]. The nucleophilic tag can 
be as short as two or three glycines for the protein ligation to work, making it popular for protein–
peptide ligation [51] with biologically as well as chemically synthetized compounds. This has been 
successfully demonstrated by either using LPXTG or Gn at the N- or C-terminus with in vitro 
modification of purified recombinant proteins and on living cells [52–54]. Attempting to circumvent the 
limitation to either terminus Antos et al. introduced a dual labeling strategy featuring Streptococcus 
pyogenes sortase A. This sortase A is capable of accepting alanines as nucleophiles. The newly ligated C-
terminus of the protein will therefore be no substrate for srtA in the second modification step. In 
combination with srtA twofold modifications via distinct reactions at N- and C-terminus can be 
conducted [55]. Most of srtA’s use in antibody systems has revolved around diagnostic approaches with 
single chain antibody fragments derivatized with fluorescent or radioactive markers [56–61]. 
Kornberger and Skerra fused a whole protein, the plant toxin gelonin, to the trastuzumab-Fab with an 
srtA approach, yielding 50% conversion [62]. Nanobodies have likewise been effectively labeled with 
fluorophores and cytotoxic payloads [63,64]. Due to the limitation to modifications of either terminus 
of the target protein, srtA has not been the preferred choice for ADC generation. Considering the so far 
preferred DAR of four, Beerli et al. could produce Kadcyla- and Adcetris-similar antibodies by 
separately fusing maytansine- and auristatin-oligoglycine to the light and heavy chain of trastuzumab 
and brentuximab [65]. They achieved around 80% toxin coupling, corresponding to a DAR of roughly 
3.2. Wagner et al. created bispecific antibodies by ligating two full antibodies with a combined strategy 
of sortase reaction and click chemistry [66]. In the meantime, the repertoire of the method has been 
extended by diversifying the tag [67] and solving solubility issues and side reactions [56,68]. 
Furthermore, depsipeptides have been introduced as substrates for N-terminal protein modification to 
address reversibility of the reaction [69]. Though comparably high enzyme concentrations are needed 
and the method is limited to in vitro protein modifications, it has been extensively used for successful 
bio-conjugation. 
Figure 2. Scheme of an antibody modification with the fromylglycine-generating enzyme. For clarity,
the reaction is only depicted in one heavy chain. R represents a moiety with an aldehyde reactive
function capable of coupling via, e.g., hydrazino-iso-Pictet-Spengler Ligation, trapped Knoevenagel
Ligation, or Wittig reaction.
2.2. Sortases
Gram positive bacteria produce sortases for the attachment of surface proteins on pentaglycine
structures of the peptidoglycane cell wall [47]. Staphylococcus aureus sortase A (srtA) is the most
frequently used enzyme for site-specific protein labelling with this transpeptidase reaction (Figure 3).
Its natural substrate recognition motif is the pentapeptide LPXTG, where X is usually glutamic
acid, besides aspartic acid or lysine [48]. In a ping-pong hydrolytic shunt-like mechanism, srtA
binds the LPXTG substrate, hydrolyzes the backbone between threonine and glycine, and generates
an acyl-enzyme intermediate. The terminal amine of the oligoglycine then acts as a nucleophile,
resulting in an amide bond formation with the C-terminal threonine of the substrate [49,50].
The nucleophilic tag can be as short as two or three glycines for the protein ligation to work,
making it popular for protein–peptide ligation [51] with biologically as well as chemically synthetized
compounds. This has been successfully demonstrated by either using LPXTG or Gn at the N- or
C-terminus with in vitro modification of purified recombinant proteins and on living cells [52–54].
Attempting to circumvent the limitation to either terminus Antos et al. introduced a dual labeling
strategy featuring Streptococcus pyogenes sortase A. This sortase A is capable of accepting alanines as
nucleophiles. The newly ligated C-terminus of the protein will therefore be no substrate for srtA in
the second modification step. In combination with srtA twofold modifications via distinct reactions
at N- and C-terminus can be conducted [55]. Most of srtA’s use in antibody systems has revolved
around diagnostic approaches with single chain antibody fragments derivatized with fluorescent or
radioactive markers [56–61]. Kornberger and Skerra fused a whole protein, the plant toxin gelonin,
to the trastuzumab-Fab with an srtA approach, yielding 50% conversion [62]. Nanobodies have
likewise been effectively labeled with fluorophores and cytotoxic payloads [63,64]. Due to the limitation
to modifications of either terminus of the target protein, srtA has not been the preferred choice for ADC
generation. Considering the so far preferred DAR of four, Beerli et al. could produce Kadcyla- and
Adcetris-similar antibodies by separately fusing maytansine- and auristatin-oligoglycine to the light
and heavy chain of trastuzumab and brentuximab [65]. They achieved around 80% toxin coupling,
corresponding t a DAR of roughly 3.2. Wag er t al. creat d bispecific antibodies by ligating two
full antibodies with a combined strategy of sortase reacti n and click chemistry [66]. In the meantime,
the repertoire of the method has been extended by diversifying the tag [67] and solving solubility
issues and side reacti ns [56,68]. Furthermore, depsipeptides ave been intr duced as substrat s for
N-terminal protein odificat on to address revers bili y of the reactio [69]. Though comparably high
enzyme conce trations are needed and the method is limited to in vitro protein modifications, it has
been extensively used for successful bio-conjugation.
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Eukaryotic transglutaminases used for protein modification are derived from the guinea pig liver as 
well as the human transglutaminase 2. However, the bacterial transglutaminase from Streptomyces 
mobaraensis (MTG) is the enzyme of choice due to its independency from calcium and its lower 
deamidation activity [73]. Transglutaminases display a certain promiscuity when it comes to the 
glutamine containing recognition sequence, which has spawned a search for a universal minimal tag. 
Besides phage display derived peptides, different heptapeptide tags with hydrophobic residues N-
terminal to the central glutamine have been used [74–76]. Farias et al. shortened the tag to an LLQGA 
motif [77]. A novel strategy was presented by Siegmund et al. by generating a disulfide bridge stabilized 
handle with an exposed glutamine modelled on a natural MTG substrate reaching ligation efficiencies 
of 85% [78]. They successfully biotinylated the therapeutic antibody cetuximab, showing the 
amenability of the tag for possible antibody–drug conjugation. The feasibility of the generation of 
antibody conjugates with the aid of MTG has been proven repeatedly at different surface accessible sites 
[6,79–81]. The product yields for the latter approaches vary between 80% and 90%. The promiscuity of 
the enzyme may generate side products, like deamidated glutamine or a transesteferification product, 
and the need for experimental verification of sites for tag introduction remains. MTG catalysis is mainly 
used in vitro, but has been done on cells as well [75]. By combining transglutaminase catalysis with 
engineered cysteine maleimide conjugation, Puthenveetil et al. created a dually labeled antibody 
reaching a DAR of 4 [82]. 
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2.3. Transglutaminases
Transglutaminases catalyze an acyl-transfer reaction to the side chain of glutamine residues of
their protein substrate (Figure 4) [70]. Depending on the acyl donor, this can result in an amide bond
between the glutamine and a primary amine, crosslinking between two proteins via a side chain
lysine of the donor protein or the deamidation of glutamine [71]. For protein labelling purposes,
the acyl-transfer reaction is preferred. While transglutaminases are specific for glutamine on the
target protein, the flexibility in terms of the amine containing acyl-donor offers diverse possibilities
for modification. In contrast to other protein-ligation strategies, the probe containing reactant is not
required to be a peptide and can simply be an alkylamine or an oligoamine as long as it contains
a primary amine [72]. Eukaryotic transglutaminases used for protein modification are derived from
the guinea pig liver as well as the human transglutaminase 2. However, the bacterial transglutaminase
from Streptomyces mobaraensis (MTG) is the enzyme of choice due to its independency from calcium
and its lower deamidation activity [73]. Transglutaminases display a certain promiscuity when it
comes to the glutamine containing recognition sequence, which has spawned a search for a universal
minimal tag. Besides phage display derived peptides, different heptapeptide tags with hydrophobic
residues N-terminal to the central glutamine have been used [74–76]. Farias et al. shortened the
tag to an LLQGA motif [77]. A novel strategy was presented by Siegmund et al. by generating
a disulfide bridge stabilized handle with an exposed glutamine modelled on a natural MTG substrate
reaching ligation efficiencies of 85% [78]. They successfully biotinylated the therapeutic antibody
cetuximab, showing the amenability of the tag for possible antibody–drug conjugation. The feasibility
of the generation of antibody conjugates with the aid of MTG has been proven repeatedly at different
surface accessible sites [6,79–81]. The product yields for the latter approaches vary between 80%
and 90%. The promiscuity of the enzyme may generate side products, like deamidated glutamine or
a transesteferification product, and the need for experimental verification of sites for tag introduction
remains. MTG catalysis is mainly used in vitro, but has been done on cells as well [75]. By combining
transglutaminase catalysis with engineered cysteine maleimide conjugation, Puthenveetil et al. created
a dually labeled antibody reaching a DAR of 4 [82].
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Inteins are protein sequences that can cleave themselves off to form a mature protein. Since they 
bear an internal endoprotease activity, their application is not an enzyme strategy in the classical sense. 
For site-specific protein modification, inteins are deployed in variations of two different ligation 
strategies, expressed protein ligation (EPL) (Figure 5) and protein trans-splicing (PTS) (Figure 6). The 
reaction mechanism involves the formation of a thioester intermediate. It is formed by the N-terminal 
cysteine of the intein. Subsequently, the transfer of the thioester to an intramolecular cysteine 
downstream of the intein sequence and the release of the intein, through the generation of a peptide 
bond between the exteins, completes the reaction. Muir et al. described EPL in 1998, therein exploiting 
an intein mutation capable of inhibiting the reaction downstream of the thioester intermediate and 
intercepting it with a synthetic peptide containing an N-terminal cysteine [83,84]. The synthetic peptide 
can in turn be a carrier for C-terminal site-specific protein modification. This has been successfully 
applied for fluorescein coupling and PEGylation [85,86]. EPL has also been used to generate monoclonal 
antibody conjugates [87,88]. Unfavorably for ADC generation reducing conditions have to be 
maintained to prevent oxidation of the accepting cysteine. For antibodies, Möhlmann et al. could 
maintain intact interchain disulfide bonds and retained binding properties [87], albeit with a product 
yield of 60%. PTS on the other hand is carried out by split inteins, first characterized in Synechocystis sp. 
PCC6803. This example consisted of separately expressed N- and C-inteins with high affinity towards 
each other fused to the N- and C-terminal half of the DnaE protein respectively. Once they assembled, 
self-cleavage similar to inteins took place forming a DnaE fusion protein [89]. This strategy also has 
been used in vitro and in the cellular environment with a protein transduction domain fused to the C-
intein to enter the cell for labeling of the intracellular protein equipped with the N-intein [90]. The 
comparatively small size of the C-intein enables coupling of synthetic peptides similar to EPL. Product 
yields of up to 80% could be achieved using PTS with antibodies. Discovery and engineering of shorter 
C-intein (6 aa) and N-intein (12 aa) sequences has extended the applicability of the method to N-terminal 
protein modification [91,92]. Faster acting split inteins and inteins less sequence dependent on the extein 
sequence have since emerged [93,94]. For comfortable labeling with thiol reactive probes the Cys-Tag 
(EAGSCS) has been employed with split inteins [95]. Recently Bachman et al. modified nanobodies N-
terminally with the help of split inteins and the Cys-Tag [96]. Han et al. generated bispecific IgG 
antibodies by producing full dimeric antibodies with a C-Intein instead of a second Fab-fragment. The 
Fab-fragment of second specificity was engineered with an N-intein and fused to the first antibody via 
PTS [97]. Downsides of both EPL and PTS are the long terminal inteins of approximately 100–150 aa 
that have to be appended to the protein of interest. While this might not be an issue for whole antibodies, 
or has been shown to be manageable for VHH, for some antibody mimetics this could lead to difficulties 
in production. 
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2.4. Inteins
Inteins are protein sequences that can cleave themselves off to form a mature protein. Since they
bear an internal endoprotease activity, their application is not an enzyme strategy in the classical
sense. For site-specific protein modification, inteins are deployed in variations of two different ligation
strategies, expressed protein ligation (EPL) (Figure 5) and protein trans-splicing (PTS) (Figure 6).
The reaction mechanism involves the formation of a thioester intermediate. It is formed by the
N-terminal cysteine of the intein. Subsequently, the transfer of the thioester to an intramolecular
cysteine downstream of the intein sequence and the release of the intein, through the generation
of a peptide bond between the exteins, completes the reaction. Muir et al. described EPL in 1998,
therein exploiting an intein mutation capable of inhibiting the reaction downstream of the thioester
intermediate and intercepting it with a synthetic peptide containing an N-terminal cysteine [83,84].
The synthetic peptide can in turn be a carrier for C-terminal site-specific protein modification. This
has been successfully applied for fluorescein coupling and PEGylation [85,86]. EPL has also been
used to generate monoclonal antibody conjugates [87,88]. Unfavorably for ADC generation reducing
conditions have to be maintained to prevent oxidation of the accepting cysteine. For antibodies,
Möhlmann et al. could maintain intact interchain disulfide bonds and retained binding properties [87],
albeit with a product yield of 60%. PTS on the other hand is carried out by split inteins, first
characterized in Synechocystis sp. PCC6803. This example consisted of separately expressed N-
and C-inteins with high affinity towards each other fused to the N- and C-terminal half of the DnaE
protein respectively. Once they assembled, self-cleavage similar to inteins took place forming a DnaE
fusion protein [89]. This strategy also has been used in vitro and in the cellular environment with
a protein transduction domain fused to the C-intein to enter the cell for labeling of the intracellular
protein equipped with the N-intein [90]. The comparatively small size of the C-intein enables coupling
of synthetic peptides similar to EPL. Product yields of up to 80% could be achieved using PTS with
antibodies. Discovery and engineering of shorter C-intein (6 aa) and N-intein (12 aa) sequences has
extended the applicability of the method to N-terminal protein modification [91,92]. Faster acting
split inteins and inteins less sequence dependent on the extein sequence have since emerged [93,94].
For comfortable labeling with thiol reactive probes the Cys-Tag (EAGSCS) has been employed with
split inteins [95]. Recently Bachman et al. modified nanobodies N-terminally with the help of split
inteins and the Cys-Tag [96]. Han et al. generated bispecific IgG antibodies by producing full dimeric
antibodies with a C-Intein instead of a second Fab-fragment. The Fab-fragment of second specificity
was engineered with an N-intein and fused to the first antibody via PTS [97]. Downsides of both EPL
and PTS are the long terminal inteins of approximately 100–150 aa that have to be appended to the
protein of interest. While this might not be an issue for whole antibodies, or has been shown to be
manageable for VHH, for some antibody mimetics this could lead to difficulties in production.
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Figure 6. Scheme of an antibody modification by trans-splicing. 
2.5. Tubulin Tyrosine Ligase 
Catalyzed by tubulin tyrosine ligase (TTL), α-tubulin is modified post-translationally by C-
terminal attachment of a tyrosine [98]. Banerjee et al. showed that TTL accepts tyrosine derivatives like 
formyl-tyrosine as a substrate [99]. For the use in other proteins, Schumacher et al. labeled a 13 aa 
peptide (VDSVEGEEEGEE), mimicking the C-terminus of α-tubulin, with TTL (Figure 7). This so-called 
Tub-Tag was introduced into proteins for efficient C-terminal modification of different proteins 
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2.5. Tubulin Tyrosine Ligase
Catalyzed by tubulin tyrosine ligase (TTL), α-tubulin is modified post-translationally by
C-terminal attachment of a tyrosine [98]. Banerjee et al. showed that TTL accepts tyrosine derivatives
like formyl-tyrosine as a substrate [99]. For the use in other proteins, Schumacher et al. labeled
a 13 aa peptide (VDSVEGEEEGEE), mimicking the C-terminus of α-tubulin, with TTL (Figure 7).
This so-called Tub-Tag was introduced into proteins for efficient C-terminal modification of different
proteins including an anti-GFP nanobody [100], achieving almost full conversion after 5 h of incubation.
Substrate flexibility of TTL was further illustrated with, among others, unnatural and biotin-containing
amino acids broadening the labeling chemistry spectrum [101]. Although limited to modification of the
C-terminus and not yet used in context of full antibodies, TTL bears the potential for ADC generation.
The tub tag’s predominant polarity could proof advantageous keeping in mind the solubility problems
with mainly hydrophobic toxins during ADC generation.
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2.6. Proteases (Trypsiligase and Subtiligase)
Proteases have been utilized for protein semi-synthesis for a long time and recently also for
protein labeling. subtiligase, a variant of the serine protease subtilisin, though currently not used
for ADC generation, is able to catalyze peptide formation, in addition to its hydrolytic activity [102].
Subtiligase has been improved by phage display for ligase activity [103]. Nonetheless, the problem
of increased hydrolysis compared to ligase activity persists. Liebscher et al. engineered trypsiligase,
a trypsin variant capable of terminal modification of proteins by cutting the short recognition sequence
YRH and ligating proteins or peptides with an N-terminal RH moiety under the requirement of
Zn2+ (Figure 8) [104]. C-terminal modification with PEG and fluorescein could also be achieved for
an anti-Her2 Fab fragment, as well as coupling of the DM1 toxin with a yield of approximately 70% via
a successive click reaction [105,106]. Though trypsiligase is only applicable to the C-terminus of the
antibody, the only 3 aa long tag presents an advantage over most other mentioned enzyme strategies.
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2.7. Phosphopantetheinyl Transferase
Phosphopantetheinyl transferases transfer the phosphopantetheinyl oiety of coenzy e to
a specific serine residue in the target protein (Figure 9) [107]. Specifically, the Sfp Phosphopantetheinyl
transferase (Sfp) fro Bacillus subtilis is valued for protein labeling. Several peptide motives recognized
by Sfp ere found, a ong others the ybbR-tag (DSLEFIASKLA). The enzyme is able to transfer small
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molecule CoA conjugates to the tag serine positioned at the N- and C-terminus and also in flexible
loops of the target protein [108–110]. Grünewald et al. recently generated antibody–drug conjugates
site-specifically labeled at different loops in the constant region of trastuzumab with the help of
different Sfp tags and achieved at least 95% conversion [111].
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2.8. SpyLigase
Zakeri et al. engineered the so-called SpyTag from the CnaB2 domain of fibronectin-binding
protein fro Streptococcus pyogenes [112]. The engineered SpyCatcher is able to mediate isopeptide
for ation of a side chain lysine and asparagine (Figure 10). This protein–peptide ligation method
was refined by Fierer et al. by splitting the enzyme into three parts, SpyTag (AHIVMVDAYKPTK),
K-Tag, (ATHIKFSKRD) and SpyLigase, which is able to fuse the two tags. They used this strategy to
polymerize affibodies [113], and Siegemund et al. applied it for the generation of ADCs [114]. Both
SpyTag and K-Tag are small, so this strategy can easily be applied to both protein termini. Furthermore,
the low reaction temperatures, while still reaching 80% conversion with whole antibody substrates,
are desirable for ADC production. The excess enzyme needed for the conversion remains a target
for optimization.
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2.9. Other Strategies
There are several further enzyme strategies that were adapted to antibody–drug conjugation
or could be useful in this context based on their validated ability to ligate proteins. Lee et al.
conjugated an anti-EGFR repebody by prenylation of a cysteine in a CaaX-motif with geranyl ketone
pyrophosphate and successive oxime ligation with aminooxylated MMAF, reaching almost full
conversion [115]. Lipoic acid ligase tagging of proteins and site-specific labeling with biotin ligase
could be useful for antibody-drug conjugation as well [116–118]. Escherichia coli biotin ligase BirA
has been used for protein labeling by Chen et al. with yields of up to 50% [117]. Comparably
small amounts of enzyme are needed, yet the 15 aa tag is longer than that used in similar strategies.
The ligase can attach a biotin analog to a lysine in the tag and the ketone group can then be labeled
specifically. Heller et al. introduced a phosphocholination reaction for protein modification by
AnkX. This Legionella pneumophila enzyme recognizes the peptide sequence TITSSYYR and adds
a phosphocholine moiety from tagged CDP-choline to the second serine [119]. Conversion rates of up
to 70% could be reached with AnkX, though it has not been used with antibodies or antibody fragment
and mimetics thus far. GlycoConnect is a labeling strategy directed at glycostructures of the antibody.
Derivatization is achieved by firstly trimming N-glycans with endoglycosidase to expose an N-acetyl
glucosamine and secondly attach a click conjugatable N-acetyl galactosamine with glycosyltransferase.
Using GlycoConnect, van Geel et al. could effectively generate nearly fully converted antibody–drug
conjugates [120]. Elimination of the antibody’s N-glycosylation might have an effect on individual
antibodies regarding blood clearance or ADCC, but the impact is in general less important for ADCs.
The long incubation times at 37 ◦C and 30 ◦C are, however, not ideal for ADC production.
3. Conclusions
The sheer number and continuous development of new labeling strategies for antibody–drug
conjugates demonstrates the interest in and importance of the issue. Besides the enzyme-based
strategies discussed here, many parallel conjugation methods are being pursued, like the incorporation
of unnatural amino acids and the design of chemically specific reaction sites in the antibody or antibody
mimetic. Due to the various enzymes available for protein conjugation, chances are good that a suitable
approach for a given protein of interest can be found as described in Table 1. Different and often
short tags may be incorporated without disrupting structure and function. Problematic properties of
antibody constructs, like stability or solubility, can be considered by testing various methods, which
differ in buffer composition, additional chemical steps, or even the option to generate the conjugation
ready antibodies by co-expressing the enzyme. Most of the enzymes mentioned here have already
been used to generate homogenous antibodies at the laboratory scale. Nonetheless, it should be
mentioned that a perfect or one-size-fits-all strategy remains elusive. Possible drawbacks include
the demand for excess enzyme, reversible and incomplete reactions, or exclusively terminal ligation.
Some of these issues have already been addressed and the different strategies could also go hand
in hand for sequential labeling or labeling at different sites, e.g., with a toxin and a fluorophore
or PEG. On the therapeutic side, a combination of antibodies and antibody mimetics, due to their
individual characteristics, is conceivable as well. While current clinically investigated ADCs are mainly
constructed using engineered cysteines, future generations of antibody–drug conjugates will likely
include chemo-enzymatic strategies.
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Table 1. Overview of enzyme-based labeling strategies including substrate motif, reaction conditions, chemical strategy, site of modification, conversion yields with
antibody or antibody mimetic substrates, drawbacks, and enzyme to substrate ratio.
Strategy Substrate Reaction Buffer Duration Labeling Strategy Locus Yields Applications Drawbacks Enzyme/Substrate(Molar)
Formylglycine-generating
enzymes CXPXR
25 mM TEAM pH 9,
50 mM NaCl, 1 mM
β-ME3
16 h at 18 ◦C
aldehyde coupling
chemistry
(HIPS-Ligation,
trapped-Knoevenagel
ligation etc.)
most surface
accessible
sites
85–95% a [44]
~95% b [40]
whole
antibodies
[37,39,40,44]
-long downstream
coupling reaction
-in vitro
conversion at
alkaline pH and
reductive
environment
0.1
Sortase A LPXTG (Gn)
50 mM Tris/HCl
pH 7.9, 150 mM NaCl,
10 mM CaCl2
4 h at 42 ◦C labeled peptide(Gn or LPXTG)
N- and
C-terminal ~80% [65]
whole antibody
[65,66]
Fab [62]
-side reactions
with proteins or
peptides with
terminal glycines
~1–3
Transglutaminase (1) LLQGA or (2)GECTYFQAYGCTE
(1) 10 mM Phosphate
buffer pH 7,
150 mM NaCl
or (2) 100 mM HEPES
pH 7
(1) 16 h at
37 ◦C or (2)
3 h at 25 ◦C
labeled alkyl- or
oligo-amine
most surface
accessible
sites
~80–90%
[78,79,81]
whole antibody
[78,79,81]
-crosslinking via
side chain lysine
-deamidation of
glutamine
(1) ~0.15–0.5 or
(2) 1
Inteins
EPL C-terminal intein(~100–150 aa)
50 mM HEPES/NaOH
pH 8, 500 mM NaCl,
50 mM MESNA
22 h
labeled peptide
with N-terminal
cysteine
C-terminal ~60% [87]
whole antibody
[87,88],
VHH [96]
-long fusion tags
-premature extein
cleavage during
expression
reduces yields
N/A c
PTS terminal intein(~100–150 aa)
50 mM HEPES/NaOH
pH 7.5, 500 mM NaCl,
5 mM DTT
24 h
labeled short
complementary
intein (6–12 aa)
N- and
C-terminal ~75% [87]
whole antibody
[87,97]
-long fusion tags
-hydrolysis or
thiolysis during
splicing yields
side products
N/A c
Tubulin Tyrosine
Ligase VDSVEGEEEGEE
20 mM MES/K pH 7,
100 mM KCl, 10 mM
MgCl2, 2.5 mM ATP,
5 mM DTT
5 h at 37 ◦C labeled tyrosine C-terminal 99% [100] VHH [100]
-limited to
C-terminus
-long tag
0.2
Trypsiligase YRH
100 mM HEPES/NaOH
pH 7.8, 0.1 mM ZnCl2,
100 mM NaCl, 10 mM
CaCl2
1 h at 20 ◦C labeled RH-peptide C-terminal 70% [106] Fab [105,106]
-remaining
proteolytic
activity generates
side products
0.1
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Table 1. Cont.
Strategy Substrate Reaction Buffer Duration Labeling Strategy Locus Yields Applications Drawbacks Enzyme/Substrate(Molar)
Phosphopantetheinyl
transferase DSLEFIASKLA
50 mM HEPES pH 7.5–8,
10 mM MgCl2
16 h at 20 ◦C labeled Coenzyme A
N-, C-terminal
and flexible
loops
95% [111]
whole
antibody
[111]
-large linker
-rather
hydrophobic tag
0.4
SpyLigase AHIVMVDAYKPTK
40 mM Na2HPO4, 20 mM
Citric acid pH 6.8, 1.5 M
Trimethylamine N-oxide
(TMAO)
24 h at 4 ◦C
iso-peptide bond
formation with
labeled
ATHIKFSKRD
peptide
C- or
N-terminal ~80% [114]
whole
antibody
[114],
affibody
[113]
-enzyme excess
needed ~3
Farnesyltransferase CVIM
50 mM Tris/HCl pH 7.4,
5 mM MgCl2, 10 µM
ZnCl2, 5 mM DTT
12 h at 30 ◦C
attachment of
aldehyde or keto
functionalized prenyl
pyrophosphate,
subsequent oxime
ligation
C-terminal ~95% [115] repebody[115]
-long downstream
coupling reaction
at low pH
-enzyme excess
needed
~2
AnkX TITSSYYR
20 mM HEPES pH 7.5,
50 mM NaCl, 1 mM
MgCl2, 1 mM DTE
3 h at 25 ◦C labeled cytidinediphosphate choline
N-, C-terminal
and in internal
loops
70% d [119]
-lower yields
-reductive
environment
0.02
Biotin ligase GLNDIFEAQKIEWHE
50 mM Bicine pH 8.3,
5 mM Mg-acetate, 4 mM
ATP
3 h at 30 ◦C
ligation of Biotin to
side-chain of lysine
and subsequent
labeling of ketone
group
N-, C-terminal
and internal
loops
~50% e [117] -long Tag-lower yields 0.065–0.13
GlycoConnect N-glycans
(1) 25 mM Tris pH 8,
(2) 25 mM Tris/HCl pH 8,
10 mM MnCl2
(1) 16 h at 37 ◦C
(2) 16 h at 30 ◦C
(1) trimming of
glycan with
endoglycosidase and
(2) attachment of a
conjugable GalNAc
derivative by
glycosyltransferase
N-glycans >95% [120]
whole
antibody
[120]
-long incubation
at >30 ◦C
-disruption of
N-glycans
(1) ~0.02
(2) ~0.015
a In vitro conversion with bacterial formylglycine-generating enzymes (FGE). b Conversion of mAbs in human FGE co-expressing Chinese Hamster Ovary (CHO) cells. c Not a classical
enzyme strategy since the inteins themselves bear endoprotease activity. Eukaryotic inteins are available, yet mostly prokaryotic inteins are used for expressed protein ligation (EPL) and
protein trans-splicing (PTS). d Yield refers to reaction with tagged SUMO protein, not yet used in antibody or antibody mimetic context. e Yield refers to reaction with cyan fluorescent
protein, not yet used in antibody context.
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